JLJessica I. Lundin

Jessica I. Lundin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jessica I. Lundin has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Persistent Organic Pollutant Determination in Killer Whale Scat Samples: Optimization of a Gas Chromatography/Mass Spectrometry Method and Application to Field Samples

    by Jessica I. Lundin, Russell L. Dills, Gina M. Ylitalo, M. Bradley Hanson, Candice K. Emmons, Gregory S. Schorr, Jacqui Ahmad, Jennifer A. Hempelmann, Kim M. Parsons, Samuel K. Wasser

    Biologic sample collection in wild cetacean populations is challenging. Most information on toxicant levels is obtained from blubber biopsy samples; however, sample collection is invasive and strictly regulated under permit, thus limiting sample numbers. Methods are needed to monitor toxicant levels that increase temporal and repeat sampling of individuals for population health and recovery models. The objective of this study was to optimize measuring trace levels (parts per billion) of persistent organic pollutants (POPs), namely polychlorinated-biphenyls (PCBs), polybrominated-diphenyl-ethers (PBDEs), dichlorodiphenyltrichloroethanes (DDTs), and hexachlorocyclobenzene, in killer whale scat (fecal) samples. Archival scat samples, initially collected, lyophilized, and extracted with 70 % ethanol for hormone analyses, were used to analyze POP concentrations. The residual pellet was extracted and analyzed using gas chromatography coupled with mass spectrometry. Method detection limits ranged from 11 to 125 ng/g dry weight. The described method is suitable for p,p′-DDE, PCBs-138, 153, 180, and 187, and PBDEs-47 and 100; other POPs were below the limit of detection. We applied this method to 126 scat samples collected from Southern Resident killer whales. Scat samples from 22 adult whales also had known POP concentrations in blubber and demonstrated significant correlations (p < 0.01) between matrices across target analytes. Overall, the scat toxicant measures matched previously reported patterns from blubber samples of decreased levels in reproductive-age females and a decreased p,p′-DDE/∑PCB ratio in J-pod. Measuring toxicants in scat samples provides an unprecedented opportunity to noninvasively evaluate contaminant levels in wild cetacean populations; these data have the prospect to provide meaningful information for vital management decisions.


  • Formulations of hormone therapy and risk of Parkinson's disease

    by Jessica I. Lundin, Thanh G.N. Ton, Andrea Z. LaCroix, W.T. Longstreth, Gary M. Franklin, Phillip D. Swanson, Terri Smith‐Weller, Brad A. Racette, Harvey Checkoway

    Hormone therapy (HT) is a class of medications widely prescribed to women in the Western world. Evidence from animal models and in vitro studies suggests that estrogen may protect against nigrostriatal system injury and increase dopamine synthesis, metabolism, and transport. Existing epidemiologic research indicates a possible reduced risk of Parkinson's disease (PD) associated with HT use. The objective of this study was to evaluate PD risk associated with specific HT formulations. Neurologist‐confirmed cases and age‐matched controls were identified from Group Health Cooperative (GHC) of Washington State. Final analysis included 137 female cases and 227 controls. Hormone therapy use was ascertained from the GHC pharmacy database, further classified as conjugated estrogens, esterified estrogens, and progestin. Ever use of HT formulation demonstrated a suggested elevated risk with esterified estrogen use (odds ratio [OR], 3.1; 95% confidence interval [CI], 1.0‐9.8), and no risk associated with conjugated estrogen use (OR, 0.6; 95% CI, 0.6‐1.3). Restricting this analysis to prescriptions that included progestin further elevated the risk associated with esterified estrogen use (OR, 6.9; 95% CI, 2.1‐22.9); again, no risk was associated with conjugated estrogen use (OR, 1.7; 95% CI, 0.6‐5.0). The findings from this study suggest an increase in PD risk associated with esterified estrogen use combined with progestin, and no risk associated with conjugated estrogen with progestin. These findings could have important implications for choice of HT in clinical practice. © 2014 International Parkinson and Movement Disorder Society


  • Screening for early detection of parkinsonism using a self-administered questionnaire: A cross-sectional epidemiologic study

    by Jessica I. Lundin, Harvey Checkoway, Susan R. Criswell, Angela J. Hobson, Rachel C. Harris, Laura M. Swisher, Bradley A. Evanoff, Brad A. Racette


    • 1 January 2011
      • No. 163,p. 407-19

    Neurodegenerative diseases.

    by Harvey Checkoway, Jessica I Lundin, Samir N Kelada

    Degenerative diseases of the nervous system impose substantial medical and public health burdens on populations throughout the world. Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS) are three of the major neurodegenerative diseases. The prevalence and incidence of these diseases rise dramatically with age; thus the number of cases is expected to increase for the foreseeable future as life spans in many countries continue to increase. Causal contributions from genetic and environmental factors are, with some exceptions, poorly understood. Nonetheless, molecular epidemiology approaches have proven valuable for improving disease diagnoses, characterizing disease prognostic factors, identifying high-risk genes for familial neurodegenerative diseases, investigating common genetic variants that may predict susceptibility for the non-familial forms of these diseases, and for quantifying environmental exposures. Incorporation of molecular techniques, including genomics, proteomics, and measurements of environmental toxicant body burdens into epidemiologic research, offer considerable promise for enhancing progress on characterizing pathogenesis mechanisms and identifying specific risk factors, especially for the non-familial forms of these diseases. In this chapter, brief overviews are provided of the epidemiologic features of PD, AD, and ALS, as well as illustrative examples in which molecular epidemiologic approaches have advanced knowledge on underlying disease mechanisms and risk factors that might lead to improved medical management and ultimately disease prevention. The chapter concludes with some recommendations for future molecular epidemiology research.